We performed this meta-analysis to better assess the relationship between plasminogen activator inhibitor-1 (PAI-1) rs1799889 polymorphism and the risk of venous thromboembolism.
Method
Eligible studies were searched in PubMed, Medline, Embase, Web of Science and CNKI. Odds ratios with 95% confidence intervals were calculated.
Result
A total of 48 studies with 14,806 participants were analyzed. No positive results were detected in overall analyses. Further subgroup analyses revealed that the PAI-1 rs1799889 polymorphism was significantly associated with the risk of venous thromboembolism in Caucasians and East Asians. When we stratified available data according to type of disease, we found that the PAI-1 rs1799889 polymorphism was significantly correlated with the risk of DVT. No any other positive results were observed in overall and subgroup analyses.
Conclusion
Our findings indicate that the PAI-1 rs1799889 polymorphism may serve as a potential biological marker for venous thromboembolism in Caucasians and East Asians.
WilburJShianB.Diagnosis of deep venous thrombosis and pulmonary embolism.Am Fam Phys2012;
86: 913–919.
2.
NaessIAChristiansenSCRomundstadP, et al.
Incidence and mortality of venous thrombosis: a population-based study.J Thromb Haemost2007;
5: 692–699.
3.
SilversteinMDHeitJAMohrDN, et al.
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.Arch Intern Med1998;
158: 585–593.
4.
HeitJASilversteinMDMohrDN, et al.
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study.Arch Intern Med2000;
160: 809–815.
5.
StreiffMB.Predicting the risk of recurrent venous thromboembolism (VTE).J Thromb Thrombol2015;
39: 353–366.
6.
MutchNJThomasLMooreNR, et al.
TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.J Thromb Haemost2007;
5: 812–817.
7.
CesariMPahorMIncalziRA.Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.Cardiovasc Ther2010;
28: e72–91.
8.
WestrickRJEitzmanDT.Plasminogen activator inhibitor-1 in vascular thrombosis.Curr Drug Targets2007;
8: 966–1002.
9.
BezginTKaymazCAkbalÖ, et al.
Thrombophilic gene mutations in relation to different manifestations of venous thromboembolism: a single tertiary center study.Clin Appl Thromb Hemost2018;
24: 100–106.
10.
D'AmicoMPastaFPastaL.Thrombophilic genetic factors PAI-1 4G-4G and MTHFR 677TT as risk factors of alcohol, cryptogenic liver cirrhosis and portal vein thrombosis, in a Caucasian population.Gene2015;
568: 85–88.
11.
OnurEKurdalATTugrulB, et al.
Is genetic screening necessary for determining the possibility of venous thromboembolism in cancer patients.Med Princ Pract2012;
21: 160–163.
12.
VuckovicBADjericMJTomicBV, et al.
Influence of decreased fibrinolytic activity and plasminogen activator inhibitor-1 4G/5G polymorphism on the risk of venous thrombosis.Blood Coagul Fibrinol2018;
29: 19–24.
13.
MoherDLiberatiATetzlaffJ, et al.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.Ann Intern Med2009;
151: 264–269.
14.
StangA.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.Eur J Epidemiol2010;
25: 603–605.
15.
AkarNYilmazEAkarE, et al.
Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A. Thromb Res2000;
97: 227–230.
16.
AkhterMSBiswasARanjanR, et al.
Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is seen in higher frequency in the Indian patients with deep vein thrombosis. Clin Appl Thrombos Hemost2010;
16: 184–188.
17.
AlfirevicSSundovZTomicS, et al.
Prognostic Value of MVD, LVD and Vascular Invasion in Lymph Node-Negative Colon Cancer[J].Hepato-gastroenterology2013;
60: 432–438.
18.
ArslanT1GüneyO.Ratiometric sensor based on imprinted quantum dots-cationic dye nanohybrids for selective sensing of dsDNA.Analytical Biochemistry2019;
13: 113540.
19.
BarcellonaDFenuLCauliC, et al.
Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis.Thromb Haemost2003;
90: 1061–1064.
20.
BedenčičMBožičMPeternelP, et al.
Major and potential prothrombotic genotypes in patients with venous thrombosis and in healthy subjects from Slovenia.Pathophysiol Haemost Thromb2008;
36: 58–63.
21.
ChenYZhangJWangP, et al.
Study on the association between the 4G/5G gene polymorphism of PAI1 promoter and the plasma content of PAI1 in patients with lower extremity deep vein thrombosis.Chin J Med Genet2005;
22: 624–627.
22.
BlackwellRE. Estrogen plus progestin and risk of venous thrombosis.JAMA2005;
293: 1573–1580.
23.
ErogluAUluACamR, et al.
Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.J BUON2006;
11: 481–484.
24.
EspinosaGFontJDolorsTàssies, et al.
Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin.Am J Med2002;
112: 37–43.
25.
MalakFNasrinBAhmadPZ. Polymorphisms in thrombophilic genes are associated with deep venous thromboembolism in an Iranian population.Meta Gene2014;
15: 505–513.
26.
FerraraFMeliFRaimondiF, et al.
The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein thrombosis.Blood Coagul Fibrinol2013;
24: 237–242.
27.
FolsomARCushmanMHeckbertSR, et al.
Prospective study of fibrinolytic markers and venous thromboembolism.J Clin Epidemiol2003;
56: 598–603.
28.
GiannakiKPolitouMRouvasA, et al.
Retinal vein occlusion: genetic predisposition and systemic risk factors.Blood Coagul Fibrinol2013;
24: 279–283.
29.
GrubicNStegnarMPeternelP, et al.
A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis.Thromb Res1996;
84: 431–443.
30.
GuligerUAlimanMGulimireT, et al.
The correlation between plasminogen activator inhibitor-1 activity and gene polymorphism and Xinjiang Uygur venous thromboembolism. J Clin Cardiovasc Dis2014;
25: 576–582.
31.
HasanNDinHAwadM.Genetic mutation in thromhophilic Egyptian patients.J Med Sci2006;
6: 591–596.
32.
KayaHKarkucakMSalifoğluH, et al.
Venöz tromboembolili hastalarda anjiyotensin dönüştürücü enzim I/D ve plazminojen aktivatör inhibitör-1 4G/5G gen polimorfizmlerinin araştırılması.Tuberk Toraks2013;
61: 88–95.
33.
KotwalSKawaguchiSAlexanderH, et al.
Thrombophilic abnormalities in patients with or without pulmonary embolism following elective spinal surgery.HSS J2013;
9: 32–35.
34.
Kuhli-HattenbachCHellsternPGlerDK, et al.
Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion.Ophthal Genet2017;
38: 413–417.
35.
KumariBSrivastavaSChatterjeeT.Study of associated genetic variants in Indian subjects reveals the basis of ethnicity related differences in susceptibility to venous thromboembolism.Thrombosis2014;
11: 1–9.
36.
KupeliEVerdiHSimsekA, et al.
Genetic mutations in Turkish population with pulmonary embolism and deep venous thrombosis.Clin Appl Thromb Hemost2011;
17: E87.
37.
LichyCKlossMReismannP, et al.
No evidence for plasminogen activator inhibitor 1 4G/4G genotype as risk factor for cerebral venous thrombosis.J Neurology2007;
254: 1124–1125.
38.
MansilhaAAraújoFSeveroM.The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and deep venous thrombosis in young people. Phlebology2005;
20: 48–52.
39.
LeonMStegnarbMMojcaB, et al.
Factor V Leiden, prothrombin 20210G → A, methylenetetrahydrofolate reductase 677C → T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous thromboembolism.Eur J Obstet Gynecol Reprod Biol2003;
111: 157–163.
40.
MorangePEHenryMTregouetD, et al.
The A-844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers.Arterioscler Thromb Vasc Biol2000;
20: 1387–1391.
41.
OguzulgenIKYilmazEDemirtasS, et al.
The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism.Clin Appl Thromb Hemost2009;
15: 73.
42.
OnurMRAkyolMPoyrazAK, et al.
Diagnosis of peritoneal metastases with abdominal malignancies: role of ADC measurement on diffusion weighted MRI.Eurasian J Med2012;
44: 163–168.
43.
OzkanMOzanMGMehmetAA, et al.
Percutaneous closure of paravalvular mitral regurgitation with Vascular Plug III under the guidance of real-time three-dimensional transesophageal echocardiography.Turk Kardiyol Dern Ars2012;
40: 632–641.
44.
PopTRVesaSCTrifaAP, et al.
PAI-1 4G÷5G and MTHFR C677T polymorphisms increased the accuracy of two prediction scores for the risk of acute lower extremity deep vein thrombosis.Rom J Morphol Embryol2014;
55: 153–157.
45.
PrabhudesaiAShettySGhoshK, et al.
Investigation of plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: a case–control study.Eur J Haematol2017;
99: 249–254.
46.
RidkerPMBakerMTHennekensCH, et al.
Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risk of myocardial infarction among middle-aged men.Arterioscler Thromb Vasc Biol1997;
17: 1687–1690.
47.
RingelsteinMBertheASchneiderT, et al.
Flow regulation in multi branched models of blood vessels.Biomed Eng2012;
57: 822–823.
48.
RingwaldJBergerAAdlerW, et al.
Genetic polymorphisms in venous thrombosis and pulmonary embolism after total hip arthroplasty: a pilot study.Clin Orthop Relat Res2009;
467: 1507–1515.
49.
RussoPDDamanteGPascaS, et al.
Thrombophilic mutations as risk factor for retinal vein occlusion: a case–control study.Clin Appl Thromb Hemost2015;
21: 373–377.
50.
TeresaSMWimanBSilviaV, et al.
4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.Thromb Haemost1998;
80: 956–960.
51.
SartoriMTDanesinCSaggioratoG, et al.
The PAI-I gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia.Clin Appl Thromb Hemost2003;
9: 299–307.
52.
SchenkJFStephanBZewingerS, et al.
Comparison of the plasminogen activator inhibitor-1 4G/5G gene polymorphism in females with venous thromboembolism during pregnancy or spontaneous abortion.Clin Hemorheol Microcircul2008;
39: 329.
53.
SegurJMVilchez-CavazosFMartinez-PastorJC, et al.
Tibial tubercle osteotomy in septic revision total knee arthroplasty[J].Archives of Orthopaedic and Trauma Surgery2014;
134: 1311–1315.
54.
StegnarMUhrinPPeternelP, et al.
The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.Thromb Haemost1998;
80: 975–979.
55.
TàssiesDGarcía de FrutosP.
Protein S deficiency and novel oral anticoagulants: An intriguing case[J].Thrombosis Research2014;
134: 1–2.
56.
VisanjiJMSeargentJTahriD, et al.
Influence of the −675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden.Br J Haematol2000;
110: 135–138.
57.
YiotiGGPanagiotouOAVartholomatosGA, et al.
Genetic polymorphisms associated with retinal vein occlusion: a Greek case–control study and meta-analysis.Ophthal Genet2013;
34: 130–139.
58.
ZhouHPanYFengC, et al.
Relationship between plasminogen activator inhibitor 1 and 4G/5G polymorphism and postoperative deep vein thrombosis.J Guiyang Med Coll2005;
30: 10–14.
59.
MatsubaraYMurataMIsshikiI, et al.
Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.Int J Hematol1999;
69: 43–47.
60.
HoekstraTGeleijnseJMSchoutenEG, et al.
Diurnal variation in PAI-1 activity predominantly confined to the 4G-allele of the PAI-1 gene.Thromb Haemost2002;
88: 794–798.
61.
BurzottaFDi CastelnuovoAAmoreC, et al.
4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction.Thromb Haemost1998;
79: 354–358.
